News related to
Stage

Dr C. J. Roy, the founder and chairman of Bengaluru-based Confident Group, died by suicide at his company office on Friday as officials from the Income Tax Department were conducting searches and questioning him, police and local authorities said. The 57-year-old was found with a gunshot wound inside his Langford Road office near Richmond Circle and was declared dead after being rushed to a hospital in HSR Layout. Authorities have launched a full investigation into the circumstances of his death, with forensic teams completing initial examinations and a post-mortem underway.

Police said staff heard a shot during the afternoon and alerted authorities, who found Roy injured in an inner room. He had reportedly been retrieving documents at the request of investigators when the incident occurred. Bengaluru Police Commissioner Seemant Kumar Singh described the case as a suspected suicide, noting that formal determinations will follow once the investigation and autopsy are complete. No suicide note has been confirmed at this stage.

The Income Tax Department’s presence at the Confident Group’s premises was part of a broad examination of financial records and compliance, which has extended over several days, according to law enforcement sources. Officers from the department were reviewing documentation linked to tax filings and other regulatory matters when Roy took his life. While some observers have drawn a link between the tax probe and his actions, senior police officials emphasised that motive has not been officially established and will be determined through detailed inquiry.

Confident Group has been a prominent name in the real estate sector for nearly two decades. Founded by Roy in 2005, the company grew from regional developments in Karnataka and Kerala to a diversified conglomerate with interests spanning residential and commercial real estate, hospitality and international ventures. The group’s portfolio included a large number of projects across southern India, and it had expanded into markets such as the UAE and the United States as part of its global strategy.

Roy, born Chiriankandath Joseph Roy and originally from Kerala, was widely recognised within Indian and international business communities. He held a PhD and had previously worked in the corporate sector before building his own enterprise into a major developer known for its ambitious projects and rapid growth. Beyond real estate, Roy was active in film production, backing several Malayalam films, and was seen as a cultural figure in his home state’s entertainment circles.

Industry analysts said the shock of his death will be felt across the real estate sector, where business leaders are already navigating a complex regulatory environment. The dual pressures of compliance with income tax requirements and ongoing litigation in tax and financial courts had placed significant strain on the leadership of Confident Group in recent months. Commentators on social media and industry platforms highlighted the need for greater support systems for executives coping with legal and financial scrutiny, although specific links between the probe and Roy’s decision are yet to be confirmed by officials.

Confident Group’s operations included a mix of residential communities, commercial complexes and mixed-use developments, with the company touting a “zero-debt” business approach that set it apart from many competitors in a sector often challenged by leveraged growth models. The firm’s international footprint, including property development in Dubai, had positioned it as a notable player in cross-border real estate development.

Family representatives and close associates have been approached by investigators as part of the inquiry, and police have indicated that statements from relatives and colleagues are being recorded to build a clearer picture of Roy’s state of mind and the events leading up to his death. As the probe continues, authorities have pledged to share further details when available.

From Stage to Screen: A Journey of Multi-Directional Development

Hailed as a “Hexagonal Warrior” for his all-around prowess, Tan Jianci has delivered eye-catching performances across multiple fields. In film and television, from the calm portraitist Shen Yi in “Under the Skin” to the impressive and stunning dual roles of Xiang Liu and Fangfeng Bei in “Lost You Forever,” he has won widespread acclaim for his nuanced and powerful acting. In 2025, his roles in the film “I Miss You” and the TV series “Under the Skin 2” earned him dual nominations for Best Actor at the Macau International Film Festival’s Golden Lotus Awards, making him the first actor ever to achieve simultaneous nominations in both film and television categories at the same ceremony.

Meanwhile, Tan Jianci has achieved remarkable success in music. His personal albums, such as “DREAMS” and “HUAN,” showcase his depth and diversity as a creator. His single “Bad Monalisa” not only dominated major charts but also won “Annual Chinese Digital Single” at the 2025 TMEA Awards, where he himself was awarded “Annual Best All-Round Singer.” At the end of 2025, the two lead singles, “PROOF” and “DEAD REFLEX,” from his third album rapidly topped daily charts on multiple music platforms upon release, once again proving his powerful appeal in music.

Furthermore, Tan Jianci actively shines in variety shows and the fashion world. In 2025, he graced the covers of three major mainstream women’s fashion magazines—”ELLE,” “Harper’s Bazaar,” and “Marie Claire”—becoming the first male celebrity that year to achieve covers on all three of these top five publications. Notably, the sales for his “ELLE” New Year issue broke industry records, showcasing his strong commercial value and fashion influence.

Tan Jianci Wax Figure Limited-Time Tour: An Immersive Star-Studded Experience

Tan Jianci’s wax figure now resides in the “Hong Kong Glamorous” zone. Dressed in a classic black suit, the figure’s highly accurate facial features and meticulous details showcase masterful craftsmanship, earning it the affectionate nickname “God of Unfiltered Photos” from fans. Running from 30 January to 12 April 2026, this nearly three-month exhibition allows visitors not only to take close-up photos with the figure but also to engage with interactive installations in the zone. The charm of Tan Jianci’s diverse talents across film, music, and fashion offers visitors a dreamy moment of being “in the frame with their idol” and embarking on a personalised star-studded journey.

Madame Tussauds Hong Kong warmly invites visitors to participate in the “Celebrate the New Year with Tan Jianci” engagement game. From 9 February to 23 February 2026, fans are encouraged to share their own creative photos or videos with Tan Jianci’s wax figure on social media. Participants should tag Tan Jianci and the official accounts of Madame Tussauds Hong Kong and include the hashtags #MeetMoreInTheNewYear and #MadameTussaudsHongKong.The most creative participants will have the chance to win a mystery gift. Welcome to The Peak to capture a unique interactive moment with Tan Jianci wax figure.

Exclusive New Year Surprises Unlocked: Multiple Perks for Festive Joy

In celebration of the New Year, Madame Tussauds Hong Kong is launching a variety of exclusive offers. From 13 February to 23 February 2026, all paid guests will receive a “Mystery Red Packet,” which contains a randomly selected mini card of a celebrity wax figure from Madame Tussauds Hong Kong—each card is a unique collectible. The attraction will also feature the “Year of the Horse Wishing Tree,” where visitors can write down their wishes for the new year, hoping that all their wishes will come true.

To further enhance the festive vibe, Madame Tussauds Hong Kong introduces a limited package—enjoy admission to Madame Tussauds Hong Kong, plus a VR experience and a selected beverage to elevate your immersive visit while sipping on a delightful drink. Adult package prices have been reduced from HKD 370 to just HKD 285.

Combo Ticket Details: Experience The Peak for HKD 390

Madame Tussauds Hong Kong is reintroducing Peak Tram combos (2-in-1 and 3-in-1) at attractive package prices for more surprises and value. From now on, visitors can purchase the following combo tickets at valued rates on the official website:

Visitors from around the world are invited to celebrate the New Year at Madame Tussauds Hong Kong, capturing unforgettable photos and creating cherished memories with Tan Jianci and more other star figures. Join the festivities and make this celebration special.
Hashtag: #MadameTussaudsHongKong #MeetMoreInTheNewYear

The issuer is solely responsible for the content of this announcement.

About Madame Tussauds

Madame Tussauds has been inviting people to walk the red carpet and get closer to the revered for over 250 years. With 17 Merlin-operated attractions in the world’s top destination cities, we are dedicated to giving millions of visitors the opportunity to mingle with the mighty from A-listers to music legends, heroes of sport, to world leaders. Today, we continue to partner with the global icons of a generation to create astonishing lifelike figures from sittings and offer exciting and interactive experiences to ensure guests have never felt closer to fame.

About Merlin Entertainments

Merlin Entertainments is a world leader in branded entertainment destinations, offering a diverse portfolio of resort theme parks, city-centre gateway attractions and LEGOLAND® Resorts which span across the UK, US, Western Europe, China and Asia Pacific. Dedicated to creating experiences that inspire joy and connection, Merlin welcomes more than 62 million guests annually to its diverse global estate in over 20 countries. An expert in bringing world-famous entertainment brands to life, Merlin works with partners including the LEGO® Group, Sony Pictures Entertainment, Peppa Pig, DreamWorks and Ferrari to create destinations where guests can immerse themselves in a wide array of brand-driven worlds, rides and uplifting learning experiences.

See www.merlinentertainments.biz for more information.

The event was officiated by Prof. Timothy TONG, Chairman of the Research Grants Council (RGC); Mr Osher GILINSKY, Vice President for Asia Pacific, Academia and Government, Clarivate; and Prof. Christopher CHAO, Senior Vice President (Research and Innovation) of PolyU, who delivered opening remarks.

Celebrating PolyU’s exceptional research achievements and their far-reaching impacts on society, the Nation and the world, Prof. Tong stated, “The PolyU Research Excellence Report vividly demonstrates its commitment to sustainable development, reflecting the dedication and innovation of its faculty, researchers and students.” Prof. Tong commended PolyU for its effective use of research resources, noting the significant advancements in AI-driven medical breakthroughs, climate solutions and sustainability. He further emphasised the RGC’s ongoing commitment to supporting research that addresses major societal challenges, exemplified by initiatives such as the Research Impact Fund. Additionally, he reaffirmed the RGC’s partnership with universities in strengthening Hong Kong’s status as a global knowledge hub.

Recognising PolyU’s outstanding global research performance, Mr Gilinsky elaborated, “In recent years, PolyU has demonstrated high research productivity in high quality, driving for high impact for the society. PolyU was granted 1,020 patents between 2020 and 2024, the second highest among UGC-funded universities. To enhance research translation, PolyU has formed partnerships with companies including NVIDIA, Huawei and Alibaba. These achievements illustrate PolyU’s international connectivity, diverse disciplinary strengths and strong culture of research translation. Leveraging its strength with the Chinese Mainland resources, PolyU is also accelerating knowledge transfer and identifying emerging areas for discovery, particularly in AI-powered healthcare, sustainable engineering, advanced manufacturing and smart city development—fields where it aims for global leadership.”

Prof. Chao emphasised, “The report is a testament to years of dedicated effort, groundbreaking innovation and the unwavering commitment of the PolyU academic community. In 2025, we are proud to have 21 PolyU scholars named Highly Cited Researchers by Clarivate, while 428 rank among Stanford University’s World’s Top 2% Most-cited Scientists—placing PolyU second among Hong Kong tertiary institutions. Our Strategic Plan 2025/26 – 2030/31, themed ‘Unite to Meet Challenges, Innovate to Benefit Society,’ will further empower PolyU to deliver even more transformative contributions to society.”

Clarivate has been forging continuous collaborations with numerous institutions, including co-authoring the report series The impact of research undertaken by universities in Hong Kong with UGC in 2022. Produced by Clarivate using authoritative data from the Web of Science, the PolyU Research Excellence Report delivers a comprehensive assessment of the University’s overall research performance and achievements, highlighting PolyU’s global leadership in engineering, advancements in powering medical research with emerging AI technologies, and unique contributions to the hospitality, fashion and textile, design and art disciplines that distinguish the University on the global stage.

PolyU’s strengths are exemplified by its leadership in Hong Kong’s research output growth, achieving the highest number of publications among UGC‑funded universities in 2024. Nearly 40% of its outputs are internationally co-authored, while 27% involve QS Top 50 university partners. The quality and impact of the University’s research output are further evidenced by its strong disciplinary performance. In the QS World University Rankings by Subject 2025, seven PolyU disciplines rank in the global Top 30, while, overall, 26 disciplines are listed among the world’s Top 100, underscoring the breadth and depth of the University’s academic excellence across multiple fields.

Following the report launch, the Impact Forum featured a high-level panel discussion on “Innovations and Challenges in Research Evaluation”. The discussion facilitated insightful exchanges between the panel and attendees on evolving approaches to research assessment, the importance of measuring societal impact and strategies for fostering cross-institutional collaboration.

Hashtag: #PolyU #Clarivate #ResearchOutput #AIMedical #Engineering #HongKong

The issuer is solely responsible for the content of this announcement.

Airport health authorities across parts of Asia have stepped up screening measures following confirmed Nipah virus infections in southern India, as governments move to limit the risk of cross-border transmission of one of the world’s deadliest zoonotic diseases. Thermal scanning, health declarations and targeted advisories for travellers arriving from affected regions have been expanded at several international gateways, according to aviation and public health officials.

Health officials say the steps reflect heightened vigilance rather than evidence of international spread. Nipah virus, which circulates naturally in fruit bats of the Pteropus genus, does not transmit easily between people but can cause severe respiratory illness and fatal encephalitis when outbreaks occur. The case fatality rate recorded in past outbreaks has ranged between 40 per cent and 75 per cent, making it a pathogen of particular concern for health systems with dense populations and high travel volumes.

Kerala has confirmed a small cluster of infections, triggering contact tracing, isolation of close contacts and temporary restrictions in affected localities. State authorities have emphasised that the outbreak remains contained, with surveillance expanded in hospitals and laboratories instructed to prioritise testing of patients with compatible symptoms. Central health agencies have issued advisories to states to strengthen infection-control protocols, especially in intensive care units.

Against this backdrop, several Asian countries have updated airport health protocols. Major hubs in Southeast Asia have reinstated temperature screening for passengers arriving from Kerala and neighbouring regions, while airlines have circulated guidance to cabin crew on recognising symptoms and handling suspected cases in flight. Travellers reporting fever, headache, cough or altered consciousness are being referred for secondary screening and medical evaluation on arrival.

Public health experts note that such measures are designed to buy time rather than eliminate risk entirely. Nipah virus has an incubation period that can extend beyond a week, meaning asymptomatic travellers may not be detected at borders. However, early identification of symptomatic cases can reduce exposure in crowded terminals and allow faster clinical intervention.

Regional travel checks widen amid Nipah concerns, health specialists say, reflecting lessons learned from previous outbreaks. Since Nipah was first identified in Malaysia in 1998 during an outbreak linked to pig farming, sporadic episodes have been recorded in Bangladesh and India, often associated with consumption of raw date palm sap contaminated by bats or close contact with infected patients. Bangladesh has reported more frequent outbreaks, with evidence of limited human-to-human transmission in hospital and household settings.

There is currently no approved vaccine or specific antiviral treatment for Nipah virus. Clinical management focuses on supportive care, including respiratory support and treatment of complications. Experimental therapies and vaccine candidates are under development, but none has reached late-stage approval. This places a premium on early detection, isolation and rigorous infection control.

Airports are a critical interface in that strategy. Aviation authorities say screening has been calibrated to avoid unnecessary disruption to travel while maintaining public confidence. Airlines operating routes to India have not reported cancellations, though some passengers have faced longer processing times at arrival halls.

Economic analysts point out that even limited health alerts can affect tourism-dependent economies if risk communication is mishandled. Governments have sought to strike a careful balance, emphasising that there is no general travel ban and that routine travel remains safe. Health ministries across the region have coordinated messaging through existing disease surveillance networks to ensure consistent guidance.

Within India, the outbreak has renewed scrutiny of zoonotic spillover risks linked to deforestation, urban expansion and climate variability. Ecologists note that changes in bat habitats can increase contact with human settlements, raising the likelihood of viral transmission. Public health planners argue that long-term prevention will require stronger integration of animal, human and environmental health policies under a “One Health” approach.

Ottawa and New Delhi are preparing for a high-level visit in March by Canadian Prime Minister Mark Carney, with negotiations entering an advanced stage on a cluster of agreements covering uranium supply, clean energy cooperation, critical minerals and artificial intelligence. Officials familiar with the talks say the visit is being positioned as a reset in economic engagement after a period of diplomatic strain, with both sides keen to lock in commercially binding deals that reflect shifting global supply chains and technology priorities.

The centrepiece of the expected package is an expansion of civil nuclear cooperation, anchored in long-term uranium supply contracts. Canada is among the world’s largest producers of uranium, while India has been seeking diversified and reliable fuel sources to support its nuclear power programme, which is projected to grow sharply over the next decade. Negotiators have been working to streamline regulatory clearances and pricing mechanisms to give utilities and suppliers greater certainty, while ensuring safeguards and compliance obligations are met.

Energy cooperation is set to extend beyond nuclear. Talks have included collaboration on clean hydrogen, carbon capture and storage, and grid-scale renewable integration. Canadian firms bring experience in cold-climate energy systems, advanced storage and emissions management, while India offers scale, manufacturing depth and ambitious deployment targets. Officials describe the approach as moving from memoranda of understanding towards projects with defined investment timelines and joint development structures.

Critical minerals form another pillar of the discussions. Canada’s reserves of lithium, nickel, cobalt and rare earths are increasingly viewed as strategic assets as governments seek alternatives to concentrated supply routes. India, pushing to build domestic battery and electronics manufacturing capacity, has been exploring offtake agreements, joint exploration and downstream processing partnerships. The proposed framework is designed to align mineral extraction with environmental and community standards, while enabling long-term supply security for manufacturers.

Artificial intelligence cooperation has emerged as a newer, fast-moving track. Policymakers on both sides have been weighing arrangements that combine Canada’s research ecosystem and talent pipeline with India’s large-scale data capabilities and application-driven innovation. Areas under discussion include healthcare diagnostics, climate modelling, financial services and public-sector digital infrastructure. Officials have emphasised the need for guardrails on data governance, intellectual property and ethical use, reflecting growing global scrutiny of AI deployment.

Trade officials say the March visit, if confirmed as planned, would also provide political momentum to broader commercial ties. Bilateral trade has grown steadily over the past decade but remains below potential, particularly in high-value manufacturing and services. Business groups in both countries have been urging clearer pathways for investment approvals, mobility of skilled professionals and dispute resolution mechanisms to reduce friction for companies operating across jurisdictions.

As a lead candidate under Immuno Cure’s patented “PD-1-Enhanced DNA Vaccine Technology Platform”, ICVAX aims to achieve sustained, immune-mediated HIV-1 virological control without the need of antiretroviral therapy. Following the successful first-in-human ICVAX Phase I clinical trial in Shenzhen that showed exceptional safety and immunogenicity profiles, this clinical study will explore the safety and immunogenicity of ICVAX in HIV-infected volunteers in Hong Kong, to be administered by three distinct delivery systems. This comparative approach will provide essential data on the optimal delivery method for ICVAX, and hence potentially identifying the most effective, patient-friendly and scalable option for enhancing immunotherapeutic responses in people living with HIV.

The clinical study will be conducted at Prince of Wales Hospital and will be led by Dr Grace LUI, Head of the Division of Infectious Diseases at CUHK Medicine’s Department of Medicine and Therapeutics, as the Principal Investigator. This is a randomized clinical study to evaluate the immunogenicity and safety of ICVAX in a total of 22 HIV-infected volunteers using three delivery systems: Teresa-EPT-1 electroporation device, PharmaJet’s Tropis, a WHO pre-qualified needle-free injection system, and PapiVax’s TriGrid EP device.

This study has been granted ΗΚ$4.2 million funding under the Public Sector Trial Scheme of the Innovation and Technology Fund of the HKSAR Government (project reference number: UTT/002/23GM). Professor Zhiwei CHEN, Director of the HKU AIDS Institute and Principal Scientific Advisor of Immuno Cure, serves as the Project Coordinator for this funding. This study is also partially supported by Theme-based Research Scheme (TRS) of the Research Grants Council under the University Grants Committee of the Education Bureau (project reference number: T11-702/24-N).

“This Phase I clinical study is an important landmark, being the first evaluation of ICVAX in Hong Kong volunteers and incorporating multiple innovative delivery technologies,” said Dr Grace LUI. “By testing these devices, we aim to optimize safety, immunogenicity, and patient experience for this promising HIV therapeutic DNA vaccine candidate.”

“ICVAX is built on the innovative PD-1-Enhanced DNA vaccine technology invented and developed locally at the HKU,” said Professor Zhiwei CHEN. “This study will help optimize delivery of ICVAX, paving the way for broader international deployment.”

“The launch of this clinical study is a major milestone of vaccine development for Immuno Cure,” said Dr Xia JIN, CEO of Immuno Cure. “By testing ICVAX for the first time in Hong Kong and comparing three innovative delivery devices this study not only advances our understanding of the performance of our DNA medicines, but also significantly supports the global commercialization of ICVAX and our other DNA medicines. Immuno Cure is committed to leading innovation in immunotherapy to combat infectious diseases and cancers.”

Hashtag: #ImmunoCure

The issuer is solely responsible for the content of this announcement.

About Immuno Cure

Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of innovative DNA medicines and antibody immunotherapies to fight against cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA Vaccine Platform and Anti-Δ42PD1 Antibody Platform

To learn more about Immuno Cure, please visit http://www.immunocure.hk.

About CUHK Medicine

Established in 1981, CU Medicine has achieved international recognition in teaching, research, and clinical practice and is the youngest medical school ranked among the world’s top 25 in many global rankings. In the “Best Global Universities Subject Rankings 2025-26” by U.S. News and World Report, its “Gastroenterology and Hepatology”, “Endocrinology and Metabolism” and “Clinical Medicine” programmes rank 1st in Asia, while Gastroenterology and Hepatology claims 2nd globally.

The Faculty comprises 14 clinical departments and five schools, delivering a world-class environment for teaching and research with a strong emphasis on interdisciplinary, interprofessional, and international collaboration. To date, it has cultivated over 6,000 medical graduates who are making an impact across local and global healthcare systems. The Faculty is dedicated to driving innovation by translating groundbreaking research into real-world clinical applications. Its contributions have reshaped medicine — evidenced by the filing of 3,000 patents, strategic patent acquisitions, and the establishment of more than 20 start-ups. Its pioneering research has not only rewritten international clinical guidelines but also revolutionised the prevention, diagnosis, and treatment of numerous diseases.

To learn more about CU Medicine, please visit http://www.med.cuhk.edu.hk.

About HKU AIDS Institute

HKU AIDS Institute was established in November 2007 to take HKU in a new strategic direction in fighting this global epidemic and help to make it a leader in the region in AIDS research, education and prevention. Scientists at the AIDS Institute are fully committed to conducting basic and applied research that facilitates the understanding of AIDS pathogenesis and the development of effective AIDS vaccines. Currently, the Institute is leading the Hong Kong Theme-based Research Scheme entitled “Potentiating Host Immunity for HIV-1 Functional Cure”.

To learn more about HKU and AIDS Institute of HKU, please visit https://www.hku.hk/ and https://www.med.hku.hk/aidsinst/.

About BAY TRIAL

BAY TRIAL is a key initiative in implementing the “Notice of the State Council on Issuing the Development Plan for the Shenzhen Park of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone” (State Council [2023] No. 12). It serves as strong support for Shenzhen’s development as an international science and technology innovation centre and for promoting the high-quality development of the biopharmaceutical industry in the Guangdong-Hong Kong-Macao Greater Bay Area (GBA). Located in the Hetao Shenzhen-Hong Kong Cooperation Zone, BAY TRIAL leverages the zone’s unique geographical and policy advantages to integrate clinical trial innovation resources across the GBA, deepen Shenzhen-Hong Kong science and technology collaboration, and establish a one-stop clinical trial platform.

To learn more about BAY TRIAL, please visit: https://baytrial.smart.org.cn/about/index.html

Alibaba Cloud and NVIDIA as Key Technology Partners. Usher in a New Era of Industrial AI.

HONG KONG SAR – Media OutReach Newswire – 26 January 2026 – AsiaInfo Technologies Limited (“AsiaInfo Technologies” or the “Company”; HKEX stock code: 01675), a leading provider of software products, solutions, and services, and ABB Robotics jointly established the “Embodied Intelligence Laboratory” and held its inauguration ceremony at AsiaInfo Plaza in Beijing on 25 January.

Tian Suning, Chairman of AsiaInfo Technologies, and Dr. Ouyang Ye, Chief Executive Office and Chief Technology Officer of AsiaInfo Technologies, together with Han Chen, Vice President of ABB Group and President of ABB Robotics China, jointly held an unveiling ceremony for the laboratory. Li Li, Vice President of the Government-Enterprise Business Unit at Alibaba Cloud Intelligence Group, attended the ceremony as key technology partners, witnessing this milestone that ushers in a new phase of integration between Physical AI technologies and the real economy.

ABB Robotics is one of the world’s leading robotics suppliers, offering a comprehensive and integrated portfolio that includes industrial and collaborative robots, autonomous mobile robots (AMRs), controllers, application solutions, services, and equipment. Powered by its intelligent software, its technologies help businesses across industries from automotive to electronics and logistics to become more resilient, flexible, and efficient.

As AI rapidly moves from the digital realm into the physical world, Physical AI, as the key bridge linking AI capabilities with real‑world industries, is becoming a core engine driving the intelligent upgrade of manufacturing sector. Against this backdrop, AsiaInfo Technologies has established a strategic partnership with ABB Robotics to jointly set up the Embodied Intelligence Laboratory, integrating both parties’ core strengths in foundation AI large models, industrial automation, communications technologies and robot control. The laboratory will focus on cutting‑edge areas such as industrial simulation and Physical AI, aiming to break through bottlenecks in the perception, decision‑making and execution capabilities of intelligent agents in complex real‑world scenarios. It will build an end‑to‑end innovation system spanning technology research and development (“R&D”), technology commercialization and large‑scale industrial deployment, thereby injecting strong AI‑driven momentum into high‑quality development.

As a leader in full‑stack digital‑intelligence capabilities, AsiaInfo Technologies will take AI large model application as the core lever, deeply integrating its strengths in 5G‑A telecommunications technology and network security to drive technology integration and large‑scale deployment at the laboratory. By developing replicable, scalable scenario‑based solutions, the Company will accelerate the rollout and value realisation of innovation in the intelligent manufacturing sector. Leveraging its global expertise in industrial automation and flexible control, ABB Robotics will provide the laboratory with real‑world, production‑line use cases and strong engineering support capabilities, enabling efficient validation, optimisation and iteration of technical solutions, and achieving deep coupling and mutual empowerment between technology and application scenarios.

The laboratory will leverage external technology partners to reinforce its R&D capabilities. By utilising Alibaba Cloud’s massive data processing power and cutting‑edge algorithmic frameworks such as Vision‑Language‑Action (VLA), and NVIDIA accelerated computing technology for training optimisation, it will significantly speeding up the industrialisation of Physical AI technologies.

The Embodied Intelligence Laboratory jointly established by AsiaInfo Technologies and ABB Robotics has been officially launched, marking the shift of their strategic partnership into a practical stage of implementation based on previous research. This collaboration represents not only a forward-looking initiative by both parties to deploy cutting-edge technologies and fulfill their industrial responsibilities, but also a pivotal step in advancing Physical AI from the laboratory into real-world applications on the factory floor. Looking forward, AsiaInfo Technologies together with partners including ABB Robotics and Alibaba Cloud, will use the laboratory as a core platform to deepen technical collaboration and scenario co‑creation, drive large‑scale deployment of Physical AI in industry, build a globally impactful benchmark for industrial intelligence, and help shape an open and collaborative Physical AI ecosystem.
Hashtag: #AsiaInfo

The issuer is solely responsible for the content of this announcement.